Table 1.

Summary of PRISM-SRM measurements of 37 urine samples

Prostate cancer patient urine Ida		L/Hb	CV	AGR2 concentration (pg/100 μg urinary protein)
				PRISM-SRM	ELISAc
Non-cancer	P07022BN	0.00172	5.9%	55.5
	P07036BN	0.00375	7.1%	127.0
	P08018BN	0.00077	13.5%	26.6
	P08022BN	0.00290	2.3%	96.5
	P08036BN	0.00197	10.5%	64.7
	P09040AN	0.00780	5.5%	305.3
	SAP12_003BN	0.00410	10.8%	137.4
	SAP12_008BN	0.00735	5.3%	251.9
	SAP12_014BN	0.00320	5.8%	106.8
	SAP12_016BN	0.00435	7.6%	144.6
	SAP12_017BN	0.00610	4.9%	207.1
	SAP12_026BN	0.02220	2.1%	805.7
	SAP12_028BN	0.00570	3.9%	193.0
	SAP12_030BN	0.00295	12.4%	97.1
	SAP12_033BN	0.00315	15.1%	105.1
	SAP12_034BN	0.00500	6.7%	168.0
	SAP12_035BN	0.01040	2.6%	361.2
	SAP12_039BN	0.01230	3.1%	429.3
	SAP12_050BN	0.01790	2.3%	630.0
	SAP12_052BN	0.00690	11.5%	235.7
	SAP12_071BN	0.00790	7.5%	271.6
	SAP12_072BN	0.00315	12.3%	105.1
	SAP12_077BN	0.00630	5.9%	214.2
Cancer	P06003Pre	0.00037	1.4%	12.1
	P06011Pre	0.00333	15.1%	112.0	21
	P06017Pre	0.00339	16.5%	114.2
	P07016Pre	0.00576	8.5%	263.4
	P07018Pre	0.01228	9.8%	494.1	78
	P07019Pre	0.00086	7.1%	30.7
	P07029Pre	0.00011	15.6%	3.0
	P07031Pre	0.02681	16.6%	963.3	208
	P07040Pre	0.00395	14.2%	120.5
	P07047Pre	0.00073	15.2%	23.5	2.3
	P08006rPre	0.00133	4.2%	48.8
	P08015Pre	0.00233	4.6%	69.8	62.5
	P08028Pre	0.00206	13.3%	68.5
	P08032Pre	0.00086	2.3%	30.8	10

^aClinical prostate cancer patient and non-cancer urine samples.

^bAverage L/H peak area ratios for three LC-SRM measurements.

^cAGR2 concentration measured by ELISA.